Loading…
← CockpitCompetitor Analysis › FLGT Fulgent Genetics, Inc.Open in the cockpit ↗

Fulgent Genetics, Inc.FLGTCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical/Nursing Services
Momentum leader 95
Mkt cap
$702M
US dollars, full cap
Free float
64%
of shares outstanding
$/day
$9.11M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-24.1 pp
WACC 10.0%
Hurdle
n/a
no reverse DCF
Next earnings
100 days
26 Feb 2027
Close · USD$25.13
1D+3.8%
1W-2.2%
1M+23.6%
3M+26.1%
6M+53.1%
YTD-4.3%
1Y-12.8%
ATR %5.0%
Beta0.98
52w lowhigh19.0% off high

What Fulgent Genetics does

Employees: 1,344

Fulgent Genetics at a glance

Size Fulgent Genetics (FLGT) is a United States Health Care company (Medical/Nursing Services) with a market value of $702M, the 2455th largest of 3,085 United States companies the cockpit tracks. Shares closed at $25.13 on 18 Nov 2026.

Performance Over six months the shares gained 53.1%, against -8.6% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd highest of 21 in its peer set.

Growth Revenue grew 4.7% over the last twelve months (peer median +6.2%); the operating margin is -37.5% (peer median 8.2%).

Valuation It trades at 1.2× enterprise value to sales against a peer median of 1.6× (7th cheapest of 21).

Capital Return on invested capital runs 24.1 points below its cost of capital (10.0% WACC).

Short interest Short interest is 7.2% of the free float (30 Oct 2026).

Next results Next results expected around 26 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026FLGT 145Peer median 92
Six months, rebased to 100: Fulgent Genetics against the median of its 20 peers (local-currency closes).

Fulgent Genetics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$330M$323M$283M$289M$619M
Revenue growth—+14%-2%-53%—
Gross profit$103M$123M$99.2M$96.6M$360M
EBITDA-$97.4M-$67.0M-$49.0M-$43.5M$218M
Net income-$90.9M-$60.5M-$42.7M-$168M$143M
Free cash flow-$1.40M-$124M-$19.3M$4.80M$235M
Capital expenditure$15.8M$22.6M$40.3M$22.2M$18.8M
Total debt$10.4M$8.04M$9.23M$14.9M$41.1M

Quarterly statements and history in the cockpit →

Fulgent Genetics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%+20%NEPHROPLUSGMRSWELL1951195940TTALOTHYROCAREDNA4694301060REGAHCO688315127120GDRXACLNUTXIDXJSLLFLGT6-month return →1-month return →
Up and to the right = strong over both horizons. Fulgent Genetics is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%2.5×5×7.5×NEPHROPLUSGMRSWELL1951195940TTALOTHYROCAREDNA4694301060REGAHCO688315127120SRTAGDRXACLNUTXIDXJSLLFLGTRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Fulgent Genetics is the large dot.

Fulgent Genetics competitors and peer comparison

How Fulgent Genetics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Fulgent Genetics against its 20 peers (data as of 18 Nov 2026)
MeasureFLGTPeer medianRank in peer set
1-month return+23.6%-1.8%highest of 21
6-month return+53.1%-8.6%2nd highest of 21
Distance from 52-week high-19.0%-30.8%6th highest of 21
Revenue growth (TTM)+4.7%+6.2%10th lowest of 21
Operating margin-37.5%8.2%3rd lowest of 21
EV / Sales1.2×1.6×7th cheapest of 21
ROIC minus cost of capital-24.1 pp-0.1 pp2nd lowest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Fulgent Genetics FLGTUnited States$702M+53%+5%-38%1.2×n/an/a
Nephrocare Health Services NEPHROPLUS.NSIndia$702M+1%+33%13%5.6×36.6%+31.6%
GMR Solutions GMRSUnited States$714M-8%-4%14%0.9×-19.6%-4.0%
WELL Health Technologies WELL.TOCanada$661M-9%+29%6%1.2×10.1%+94.5%
Jinxin Fertility 1951.HKHong Kong$758M-4%+7%11%2.8×17.8%+12.4%
HK inno.N 195940.KSSouth Korea$783M-28%+7%12%1.3×-4.7%+12.2%
Terveystalo Oy TTALO.HEFinland$832M-26%-8%8%1.2×-5.1%+5.3%
Thyrocare Technologies THYROCARE.NSIndia$858M+7%+22%26%8.5×28.5%+10.9%
Ginkgo Bioworks DNAUnited States$547M+9%-44%-242%6.5×n/an/a
BML 4694.TJapan$932M+12%+4%7%0.7×-9.0%+1.6%
Shanghai Labway Clinical Laboratory 301060.SZChina$518M-17%-19%6%2.3×5.9%+3.2%
Regis Healthcare REG.AXAustralia$962M-28%+17%4%0.9×13.3%+14.4%
AdaptHealth AHCOUnited States$1.01B-30%-3%3%0.9×16.8%+25.2%
Novogene 688315.SSChina$1.01B+13%+6%7%2.2×13.9%+8.2%
JS Link 127120.KSSouth Korea$458M-62%+39%-83%25.2×n/an/a
Strata Critical Medical SRTAUnited States$443M-10%+23%-4%1.4×n/an/a
GoodRx GDRXUnited States$1.15B+33%-2%12%1.8×6.3%+7.7%
Australian Clinical Labs ACL.AXAustralia$418M+68%-1%8%1.3×4.3%+2.6%
Nutex Health NUTXUnited States$1.19B+42%-19%39%1.8×-18.0%+253.5%
Integral Diagnostics IDX.AXAustralia$413M-22%+26%9%1.5×7.8%+17.7%
Jeena Sikho Lifecare JSLL.NSIndia$394M-55%+135%32%4.0×7.3%+42.6%

Questions

Which companies are Fulgent Genetics's closest peers?
The cockpit's peer set: Nephrocare Health Services (NEPHROPLUS.NS), GMR Solutions (GMRS), WELL Health Technologies (WELL.TO), Jinxin Fertility (1951.HK), HK inno.N (195940.KS), Terveystalo Oy (TTALO.HE), Thyrocare Technologies (THYROCARE.NS), Ginkgo Bioworks (DNA).
Is Fulgent Genetics expensive compared with its peers?
On ev / sales it trades at 1.2× against a peer median of 1.6×, 7th cheapest of 21 in its peer set.
How has Fulgent Genetics stock performed?
Over six months to 18 Nov 2026 the shares returned +53.1% against -8.6% for the median peer; over one year -12.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.